Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Anthera Pharmaceuticals has entered into a license agreement with Amgen for the exclusive and worldwide rights to develop and commercialize AMG 623, a peptide fusion protein, for the treatment of systemic lupus erythematosus and other autoimmune diseases.
Subscribe to our email newsletter
AMG 623, which has completed Phase Ib studies in systemic lupus erythematosus patients, is a peptide fusion protein that binds to B-cell activating factor (BAFF). Anthera anticipates initiating Phase II studies in 2008.
Paul Truex, president and CEO of Anthera Pharmaceuticals, said: “AMG 623 has the potential to be an important treatment for a variety of immunological diseases, such as lupus, where there is a need for therapies with improved safety and efficacy.”